Filing Details

Accession Number:
0001628280-21-025683
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-30 16:17:50
Reporting Period:
2021-12-28
Accepted Time:
2021-12-30 16:17:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
727207 Accelerate Diagnostics Inc AXDX Laboratory Analytical Instruments (3826) 841072256
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1021412 W Jack Schuler C/O Accelerate Diagnostics, Inc.
3950 S. Country Club Road, Suite 470
Tucson AZ 85714
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-28 30,000 $4.87 18,480,631 No 4 P Indirect By Jack W. Schuler Living Trust
Common Stock Acquisiton 2021-12-29 27,062 $4.83 18,507,693 No 4 P Indirect By Jack W. Schuler Living Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Jack W. Schuler Living Trust
No 4 P Indirect By Jack W. Schuler Living Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 54,975 Indirect By Spouse
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.79 to $4.96, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
  2. The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.90, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.